Volume 135, Issue 5, Pages (November 2008)

Slides:

Advertisements

Similar presentations

Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease Richard N. Fedorak, *, Alfred Gangl, ‡, Charles.

Advertisements

Crohn's disease Prof Daniel C Baumgart, MD, Prof William J Sandborn, MD The Lancet Volume 380, Issue 9853, Pages (November 2012) DOI: /S (12)

Volume 137, Issue 4, Pages (October 2009)

Volume 145, Issue 5, Pages (November 2013)

Volume 134, Issue 7, Pages (June 2008)

Hirschsprung's Disease With Impending Abdominal Compartment Syndrome

Guillaume Bouguen, Barrett G. Levesque, Brian G

Volume 146, Issue 3, Pages e1 (March 2014)

Volume 138, Issue 2, Pages (February 2010)

Investigation of Outbreak of Infections Caused by Salmonella Saintpaul

Volume 135, Issue 4, Pages (October 2008)

Volume 137, Issue 5, Pages e2 (November 2009)

Covering the Cover Gastroenterology

Survival of Patients With Superficial Esophageal Adenocarcinoma After Endoscopic Treatment vs Surgery Saowanee Ngamruengphong, Herbert C. Wolfsen, Michael.

Heterogeneity in Definitions of Endpoints for Clinical Trials of Ulcerative Colitis: A Systematic Review for Development of a Core Outcome Set Christopher.

Volume 147, Issue 4, Pages e7 (October 2014)

Volume 133, Issue 1, Pages (July 2007)

Covering the Cover Gastroenterology

Ira J. Fox, Stephen C. Strom Gastroenterology

Hirschsprung's Disease With Impending Abdominal Compartment Syndrome

Volume 134, Issue 7, Pages (June 2008)

Volume 135, Issue 5, Pages (November 2008)

Volume 150, Issue 7, Pages e1 (June 2016)

Volume 150, Issue 4, Pages (April 2016)

Jennifer J. Williams, Gilaad G. Kaplan, Sapna Makhija, Stefan J

Gary R. Lichtenstein, Brian G. Feagan, Russell D. Cohen, Bruce A

Volume 155, Issue 5, Pages e2 (November 2018)

Volume 130, Issue 2, Pages (February 2006)

Volume 155, Issue 1, Pages (July 2018)

Volume 147, Issue 3, Pages e3 (September 2014)

Volume 136, Issue 1, Pages (January 2009)

A Test-based Strategy Is More Cost Effective Than Empiric Dose Escalation for Patients With Crohn's Disease Who Lose Responsiveness to Infliximab Fernando.

Volume 132, Issue 5, Pages (May 2007)

Volume 143, Issue 5, Pages (November 2012)

Volume 137, Issue 4, Pages (October 2009)

Adalimumab Induces Deep Remission in Patients With Crohn's Disease

William J. Sandborn, Stefan Schreiber, Brian G

Volume 146, Issue 4, Pages e2 (April 2014)

Volume 154, Issue 6, Pages (May 2018)

Volume 132, Issue 1, Pages (January 2007)

Volume 146, Issue 1, Pages e3 (January 2014)

Rafael Esteban, Maria Buti Gastroenterology

David H. Bruining, William J. Sandborn

Melena and Hyperammonemic Seizures in a Turner Syndrome Patient

A Selection of the Best AGA Abstracts of DDW 2017

Volume 133, Issue 2, Pages (August 2007)

Antoine Debourdeau, Anne Bozon, Romain Altwegg Gastroenterology

Volume 149, Issue 6, Pages (November 2015)

Genetic Risk Profiling and Prediction of Disease Course in Crohn's Disease Patients Liesbet Henckaerts, Kristel Van Steen, Isabel Verstreken, Isabelle.

Volume 150, Issue 7, Pages (June 2016)

Decreasing Mortality Among Patients Hospitalized With Cirrhosis in the United States From 2002 Through 2010 Monica L. Schmidt, A. Sidney Barritt, Eric.

Multiple Unusual Ulcerated Skin Lesions in a Crohn's Disease Patient

Correlation Between the Crohn's Disease Activity and Harvey–Bradshaw Indices in Assessing Crohn's Disease Severity Severine Vermeire, Stefan Schreiber,

Safety of Long-term Treatment With Certolizumab Pegol in Patients With Crohn's Disease, Based on a Pooled Analysis of Data From Clinical Trials Edward.

Covering the Cover Gastroenterology

The Dawning of a New Editorial Board for Gastroenterology

Volume 135, Issue 2, Pages (August 2008)

Richard J. Saad, William D. Chey Gastroenterology

Volume 142, Issue 3, Pages (March 2012)

Volume 142, Issue 5, Pages e2 (May 2012)

Nicolas Williet, William J. Sandborn, Laurent Peyrin–Biroulet

Relationships Between Disease Activity and Serum and Fecal Biomarkers in Patients With Crohn's Disease Jennifer Jones, Edward V. Loftus, Remo Panaccione,

Changing of the Guards: 2011–2016 Gastroenterology Team

Volume 145, Issue 5, Pages e3 (November 2013)

Volume 139, Issue 6, Pages e1 (December 2010)

Capsule Endoscopy for Refractory Iron Deficiency Anemia in Crohn’s Disease: Captivating Pathology, Hybrid Therapy Long Le, Brian M. Fung, James H. Tabibian

Electronic Clinical Challenges and Images in GI

Medical Therapy for Refractory Pediatric Crohn’s Disease

Volume 153, Issue 5, Pages (November 2017)

Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis Jean-Frédéric Colombel,

Presentation transcript:

Volume 135, Issue 5, Pages 1493-1499 (November 2008) Effects of Adalimumab Therapy on Incidence of Hospitalization and Surgery in Crohn's Disease: Results From the CHARM Study Brian G. Feagan, Remo Panaccione, William J. Sandborn, Geert R. D'Haens, Stefan Schreiber, Paul J. Rutgeerts, Edward V. Loftus, Kathleen G. Lomax, Andrew P. Yu, Eric Q. Wu, Jingdong Chao, Parvez Mulani Gastroenterology Volume 135, Issue 5, Pages 1493-1499 (November 2008) DOI: 10.1053/j.gastro.2008.07.069 Copyright © 2008 AGA Institute Terms and Conditions

Figure 1 Kaplan–Meier analysis of risk of all-cause hospitalization in different treatment groups in the CHARM trial. Kaplan–Meier method was used to estimate hospitalization risk. Randomization (week 4) was used as a starting date. Log-rank test for equality over strata demonstrated that hospitalization risk of patients on placebo regimen was significantly different than the hospitalization risk of patients on adalimumab every other week (P < .01), adalimumab weekly (P < .01) and patients in the combined adalimumab group (P < .01). Gastroenterology 2008 135, 1493-1499DOI: (10.1053/j.gastro.2008.07.069) Copyright © 2008 AGA Institute Terms and Conditions

Figure 2 Kaplan–Meier analysis of risk of Crohn's disease–related hospitalization in different treatment groups in the CHARM trial. Kaplan–Meier method was used to estimate hospitalization risk. Randomization (week 4) was used as a starting date. Log-rank test for equality over strata showed that hospitalization risk of patients on placebo regimen was significantly different from the hospitalization risk of patients on adalimumab every other week (P = .02), adalimumab weekly (P < .001), and patients in the combined adalimumab group (P = .01). Gastroenterology 2008 135, 1493-1499DOI: (10.1053/j.gastro.2008.07.069) Copyright © 2008 AGA Institute Terms and Conditions